> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Clinical Hold on Quantum IND
- URL: https://www.fdaweb.com/clinical-hold-on-quantum-ind/
- Published: 2026-06-09T12:00:00.000Z
- Updated: 2026-09-14T13:40:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161283

FDA has placed a clinical hold on the Quantum BioPharma IND for Lucid-21-302, the company’s drug candidate to treat multiple sclerosis. According to a Quantum [statement](https://feeds.issuerdirect.com/news-release.html?newsid=8734002704076451&symbol=QNTM&ref=fdaweb.com), the hold is pending submission of additional information requested by FDA. Quantum says it is reviewing FDA’s comments and will work closely with the agency to address the matters identified in the letter.

Lucid-21-302 is described as a patented new chemical entity that has been shown in preclinical models to inhibit myelin degradation, a mechanism associated with multiple sclerosis.